Wuxi Genyrel Completes Nearly RMB 100 Million Series B – Funding to Advance iPSC‑Derived Universal Cell Therapy CG101 and GMP Manufacturing Build‑Out

Fineline Cube
4 Min Read
Summarize with AI

Wuxi Genyrel Therapeutics, Co. Ltd. announced that it has completed a Series B financing round of nearly RMB 100 million, co‑invested by the Wuxi Xichuang Xingwu Equity Investment Fund, managed by Wuxi Innovation Investment Group, and the Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership). Proceeds will primarily support international multi‑center clinical development of the company’s core cell therapy products, pipeline expansion into next‑generation cell therapies and innovative biologics, and construction of its R&D and GMP manufacturing base in Wuxi.

- Advertisement -

Financing Snapshot

ItemDetail
CompanyWuxi Genyrel Therapeutics, Co. Ltd. (private)
RoundSeries B – nearly RMB 100 million
Co‑InvestorsWuxi Xichuang Xingwu Equity Investment Fund (managed by Wuxi Innovation Investment Group); Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership)
Announcement Date16 Nov 2026
Use of ProceedsInternational multi‑center clinical development; next‑generation cell therapy and innovative biologics pipeline; R&D and GMP manufacturing base in Wuxi

Lead Asset Profile – CG101 Injection

  • Product: CG101 Injection, the company’s core clinical‑stage candidate.
  • Modality: A universal, off‑the‑shelf gene‑edited immune cell therapy developed on human induced pluripotent stem cell (iPSC) technology — an allogeneic approach designed to bypass the cost, vein‑to‑vein time, and manufacturing variability of autologous cell therapies.
  • Primary Indication: Acute myeloid leukemia (AML).
  • Regulatory Status: Received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) in August 2026 to conduct Phase I clinical studies.
  • Development Trajectory: With FDA IND clearance secured, the Series B proceeds are earmarked to advance international multi‑center clinical development, aligning the program with a global registrational strategy.

Company Profile & Strategic Focus

  • Mission: Genyrel Therapeutics focuses on the R&D and industrialization of innovative cell therapies and innovative biologics, targeting new treatment options for patients with malignant tumors and autoimmune diseases.
  • Platform Strategy: The iPSC technology platform underpins off‑the‑shelf cell therapy development, with pipeline expansion into next‑generation cell therapies supported by this round.
  • Manufacturing Build‑Out: Accelerated construction of the R&D and GMP manufacturing base in Wuxi is intended to support technology platform upgrades and future industrialization — a critical capability for scalable allogeneic cell therapy supply.
  • Investor Base: The round pairs regional government‑linked capital (Wuxi Innovation Investment Group) with corporate‑affiliated health industry investment (Vivo Suzhou fund), reflecting mixed public‑private backing typical of China’s advanced therapy ecosystem.

Market Impact & Outlook

  • Off‑the‑Shelf Cell Therapy Race: Universal iPSC‑derived therapies represent a leading frontier in next‑generation cell therapy, aiming to make curative‑intent treatment accessible at scale in hematologic malignancies such as AML.
  • AML Unmet Need: Acute myeloid leukemia remains a difficult‑to‑treat malignancy with high relapse rates and limited options for patients ineligible for intensive chemotherapy or transplant, sustaining demand for novel cellular approaches.
  • U.S. Clinical Footprint: The August 2026 FDA IND clearance positions CG101 for Phase I studies in the U.S., and Series B funding for international multi‑center trials signals an early global development posture rather than a China‑only strategy.
  • Industrialization Focus: Concurrent GMP base construction addresses the manufacturing bottleneck that has constrained many allogeneic cell therapy programs, supporting the company’s transition from clinical development toward commercial‑scale supply.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the use of Series B proceeds, international multi‑center clinical development of CG101, pipeline expansion into next‑generation cell therapies and biologics, construction of the R&D and GMP manufacturing base, and future regulatory interactions. Actual results may differ due to risks including clinical trial outcomes, manufacturing scale‑up execution, regulatory requirements in multiple jurisdictions, and competitive dynamics in allogeneic cell therapy. No clinical data, trial timelines, or valuation figures have been disclosed.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *